Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 12

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 12
---
holders of record at the close of business on the Record Date of [●], 2025 are entitled to vote at the Special Meeting. As of [●], 2025, there were [●] shares of our common stock issued and outstanding. Each share of common stock is entitled to one vote on each matter properly brought before the Special Meeting. Where and when is the Special Meeting? The Special Meeting is scheduled to be held online on [●], 2025at [●] Pacific Time. You will be able to attend the Special Meeting virtually by visiting www.virtualshareholdermeeting.com/AADI2025SM, where you will be able to listen to the Special Meeting live, submit questions and vote online by entering the control number on your proxy card or voter instruction form. We encourage you to complete your registration as soon as possible if you desire to attend the Special Meeting. Online registration for the Special Meeting will begin on [●], 2025, and you should allow ample time for the online registration. Please be sure to follow the instructions you will receive once your registration is complete. If you encounter any difficulties accessing the virtual Special Meeting, please contact technical support by following the instructions provided to you upon registration for the Special Meeting. What is the Divestiture? The Divestiture is the sale of 100% of the outstanding shares of capital stock of Aadi Sub from Aadi to Kaken and thereby all or substantially all of Aadi’s assets related to its FYARRO Business, pursuant to the terms of the Divestiture Agreement. Kaken will also acquire all rights to the “Aadi” name and trademark under the terms of the Divestiture Agreement. The Divestiture may be deemed to be a sale of substantially all of Aadi’s assets under Section 271 of the DGCL. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Why am I being asked to vote on the Divestiture? The Divestiture may constitute the sale of substantially all of the assets of Aadi under Section 271 of the DGCL. We are seeking the approval of Aadi stockholders for the Divestiture because the question of whether the Divestiture constitutes the sale of substantially all of the assets of Aadi under the DGCL is highly fact-specific, and because Aadi’s board of directors considered the action appropriate and strongly desire the input of Aadi stockholders, given the financial significance of the FYARRO